Establishment Labs Holdings Inc. has announced impressive financial results for the third quarter of 2026, showcasing a 33.9% increase in revenue compared to the same period last year. This growth is primarily attributed to a remarkable 119% rise in U.S. sales, marking a pivotal moment for the company as it also recorded its first quarter of positive operating and free cash flow.

The company, which specializes in orthopedic, prosthetic, and surgical appliances and supplies, reported total revenue of $72.0 million for the quarter ended September 30, 2026, up from $53.8 million in the third quarter of 2025. Establishment Labs has also raised its revenue guidance for the full year, reflecting its strong performance and optimistic outlook.

Background

Establishment Labs Holdings Inc. is a global medical technology company focused on improving women's health and wellness, particularly in breast aesthetics and reconstruction. The company is listed on the Nasdaq under the ticker symbol ESTA and operates within the SIC category of 3842, which pertains to orthopedic, prosthetic, and surgical appliances and supplies.

Recent filings show that the company has been active in reporting its financial activities, with the latest 8-K filed on October 29, 2026, detailing its financial results and corporate highlights. The filing indicates a growing trend in the company's performance, following a series of recent filings that reflect its ongoing operational developments.

What the Filing Says

According to the latest filing, Establishment Labs issued a press release on October 29, 2026, announcing its financial results for the third quarter. The release highlighted a total revenue of $72.0 million, representing a growth of 33.9% year-over-year, driven by a significant increase in U.S. sales.

"U.S. revenue increased 119.0% to $26.0 million, while OUS revenue increased 9.7% to $46.0 million," the report stated. Additionally, the company noted that its minimally invasive revenue surged by 124.0% year-over-year, reaching approximately $9 million.

Impact

This robust growth in revenue and the achievement of positive cash flow may have significant implications for various stakeholders, including investors, healthcare providers, and competitors in the orthopedic and surgical appliance industry. The increase in U.S. sales, in particular, indicates a strong demand for Establishment Labs' products, which could prompt competitors to reassess their strategies in this evolving market.

Furthermore, the company's expansion of its commercial footprint in the U.S. to over 2,100 accounts and the training of more than 400 plastic surgeons on its Preservé system suggest a growing acceptance and integration of its products in the medical community.

What's Next

Looking ahead, Establishment Labs is expected to continue its momentum as it progresses with FDA reviews for its Motiva implants for breast reconstruction. The filing does not specify any immediate next steps but indicates that the company is poised for further growth in the coming quarters.

As Establishment Labs sets a higher revenue forecast for the year, it will be crucial for industry players to monitor its developments closely, particularly as it navigates the competitive landscape of orthopedic, prosthetic, and surgical appliances.